IOVA vs SNY
Iovance Biotherapeutics, Inc. vs Sanofi — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
SNY
Sanofi
62
Insufficient Data
| Metric | IOVA | SNY |
|---|
| AI Score |
67
|
62
|
| Price |
$6.49
|
$43.56
|
| P/E Ratio |
-9.27×
|
23.06×
|
| ROE |
-56.0%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
72.8%
|
| Debt / Equity |
0.06×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
79.2
|
53.1
|
| Beta |
0.701
|
0.278
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for IOVA versus SNY.
IOVA leads by 5 points.
IOVA scores 67/100 (Buy) versus SNY at 62/100 (Insufficient Data).
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical